Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study

被引:19
|
作者
Dauden, E. [1 ]
Pujol, R. M. [2 ]
Sanchez-Carazo, J. L. [3 ]
Toribio, J. [4 ]
Vanaclocha, F. [5 ]
Puig, L.
Yebenes, M. [6 ]
Sabater, E. [6 ]
Casado, M. A. [6 ]
Caloto, M. T. [2 ,7 ]
Aragon, B. [7 ]
机构
[1] Hosp La Princesa, Madrid, Spain
[2] Hosp Mar, Barcelona, Spain
[3] Hosp Gen Valencia, Valencia, Spain
[4] CHU Santiago Hosp Gil Casares, Santiago De Compostela, Spain
[5] Hosp 12 Octubre, Madrid, Spain
[6] Pharmacoecon & Outcomes Res Iberia, Madrid, Spain
[7] Merck Sharp & Dohme Outcomes Res Unit, Madrid, Spain
来源
ACTAS DERMO-SIFILIOGRAFICAS | 2013年 / 104卷 / 09期
关键词
Psoriasis; Quality of life; Short-Form; 36; EuroQol-5D; Dermatology Life Quality Index; Psoriasis Disability Index;
D O I
10.1016/j.ad.2013.03.005
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Psoriasis is associated with a deterioration in the health-related quality of life (HRQoL) of affected patients. The aim of this study was to assess the HRQoL of patients with moderate-to-severe psoriasis. Methods: A prospective observational study (the VACAP Study) was carried out in 123 centers in Spain with 1217 patients. Patients were evaluated at baseline (visit 1 [V1]) and again four months later (visit 2 [V2]). The severity of psoriasis was determined using the following indices: (i) Psoriasis Area and Severity Index (PASI) (score range 0-72, higher score indicates more severe disease), (ii) the body surface area (BSA) affected, and (iii) the Physicians Global Assessment (PGA) (range 1-7, higher score indicates more severe disease). Four questionnaires were used for the assessment of the HRQoL: (i) the Short-Form 36 quality-of-life questionnaire (SF-36) (score range 0-100, higher score indicates better HRQoL); (ii) Euroqol (EQ-5D) (range from 1 to 3, lower score indicates better HRQoL); (iii) Dermatology Life Quality Index (DLQI) (ranges 0-30; from best to worst HRQoL); and (iv) Psoriasis Disability Index (PDI) (ranges 0-45; higher score indicates better HRQoL). Results: The mean (SD) age of the patients was 45.11 (13.92) years at V1. The mean age at the onset of psoriasis was 26.08 (14.19) years. The majority of patients were female (61%) and were employed (68%). The mean PASI score was 13.24 (9.50) at V1 and 5.07 (6.03) at V2 (P<.001). Scores from the generic HRQoL questionnaires (EQ-5D. SF-36) showed significant improvement between visits in all dimensions measured (P<.001). The disease-specific questionnaires also revealed overall improvements in quality of life over time: the DLQI mean total score was 8.97 (7.28) at V1 and 4.76 (5.72) at V2 (P<.001), and the PDI mean total score was 9.24 (8.76) V1 and 4.88 (6.65) at V2 (P<.001). Multivariate analysis using PDI as the dependent variable showed that the principal factors related to HRQoL were severity of psoriasis as measured by PASI (P<.001), and gender (P=.048). Conclusions: The principal factor related to HRQoL in patients with psoriasis is the severity of the disease. (C) 2012 Elsevier Espana, S.L. and AEDV. All rights reserved.
引用
收藏
页码:807 / 814
页数:8
相关论文
共 50 条
  • [41] Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study
    Galica, Katarzyna
    Lesiak, Aleksandra
    Ciazynska, Magdalena
    Noweta, Marcin
    Bednarski, Igor
    Narbutt, Joanna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2021, 38 (06): : 973 - 978
  • [42] The impact of demographic and clinical characteristics on the trajectories of health-related quality of life among patients with Fabry disease
    Sigurdardottir, Solrun
    Bjerkely, Birgitte
    Jenssen, Trond G.
    Mathisen, Per
    von der Lippe, Charlotte
    Orstavik, Kristin
    Heimdal, Ketil
    Dahle, Dag Olav
    Weedon-Fekjaer, Mina Susanne
    Solberg, Olga
    Pihlstrom, Hege K.
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [43] The impact of demographic and clinical characteristics on the trajectories of health-related quality of life among patients with Fabry disease
    Solrun Sigurdardottir
    Birgitte Bjerkely
    Trond G. Jenssen
    Per Mathisen
    Charlotte von der Lippe
    Kristin Ørstavik
    Ketil Heimdal
    Dag Olav Dahle
    Mina Susanne Weedon-Fekjær
    Olga Solberg
    Hege K. Pihlstrøm
    Orphanet Journal of Rare Diseases, 16
  • [44] EMPATHY Life in Psoriasis: Embracing Patients' Well-Being in Their Journey of Moderate-to-Severe Psoriasis
    Prignano, Francesca
    Campione, Elena
    Parodi, Aurora
    Vegni, Elena
    Bardazzi, Federico
    Borroni, Riccardo G.
    Burlando, Martina
    Cinotti, Elisa
    Dini, Valentina
    Giacchetti, Alfredo
    Giofre, Claudia
    Megna, Matteo
    Zichichi, Leonardo
    Fargnoli, Maria Concetta
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (15)
  • [45] Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study
    Loft, Nikolai Dyrberg
    Egeberg, Alexander
    Rasmussen, Mads Kirchheiner
    Bryld, Lars Erik
    Gniadecki, Robert
    Dam, Tomas Norman
    Iversen, Lars
    Skov, Lone
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (13) : 1224 - 1230
  • [46] Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
    Verbenko, Dmitry A.
    Karamova, Arfenya E.
    Artamonova, Olga G.
    Deryabin, Dmitry G.
    Rakitko, Alexander
    Chernitsov, Alexandr
    Krasnenko, Anna
    Elmuratov, Artem
    Solomka, Victoria S.
    Kubanov, Alexey A.
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (01): : 1 - 12
  • [47] The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients
    Young, Melodie S.
    Horn, Elizabeth J.
    Cather, Jennifer C.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (01) : 9 - 13
  • [48] Health-related quality of life in patients with psoriasis: a systematic review of the European literature
    Montse Obradors
    Carles Blanch
    Marta Comellas
    Montse Figueras
    Luis Lizan
    Quality of Life Research, 2016, 25 : 2739 - 2754
  • [49] Health-related quality of life in patients with psoriasis: a systematic review of the European literature
    Obradors, Montse
    Blanch, Carles
    Comellas, Marta
    Figueras, Montse
    Lizan, Luis
    QUALITY OF LIFE RESEARCH, 2016, 25 (11) : 2739 - 2754
  • [50] The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis
    Frieder, Jillian
    Kivelevitch, Dario
    Fiore, Connie Tran
    Saad, Saadeddine
    Menter, Alan
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (01) : 1 - 19